A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions

Current Medical Research and Opinion

Volumn 30, Issue 9, 2014, Pages 1813-1820

  Steinmetz, T ^a   Kindler, M ^b   Lange, O ^c   Vehling Kaiser, U ^d   Kuhn, A ^e   Hellebrand, E ^e  

^a Outpatient Clinic for Oncology and Haematology   (Germany)

^b Onkologische Schwerpunktpraxis   (Germany)

^c Hochschule Bonn Rhein Sieg   (Germany)

^d Praxis Hämatologie Onkologie Palliativmedizin Tagesklinik   (Germany)

^e Amgen Research GmbH   (Germany)

Author keywords

Cancer associated anemia; Observational study; Treatment practice

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; ANEMIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; FEMALE; GERMANY; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PRACTICE GUIDELINE; PROSPECTIVE STUDY; QUALITY OF LIFE; REGISTER; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; ERYTHROPOIETIN; FEMALE; GERMANY; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGISTRIES; YOUNG ADULT;

EID: 84906838973     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.924914     Document Type: Article

References (48)

1. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
2. Bokemeyer C, Oechsle K, Hartmann JT. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Investig 2005;35(Suppl 3):26-31
3. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996;201:553-8
4. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-83
5. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J radiat Oncol Biol Physics 2001;50:705-15
6. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
7. Waters JS, O'Brien ME, Ashley S. Management of anemia in patients receiving chemotherapy. J Clin Oncol 2002;20:601-3
8. Barrett-Lee P, Bokemeyer C, Gascon P, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10:743-57
9. Birgegard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 2006;77:378-86
10. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
11. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Canc 2001;84(Suppl 1):31-7
12. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28(2 Suppl 8):7-14
13. Cella D. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park, NY) 2002;16(9 Suppl 10):125-32
14. Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol 2012;3:177-91
15. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia. Ann Oncol 2013;24:475-82
16. Aapro M, Osterborg A, Gascon P, et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012;23:1954-62
17. Steinmetz T, Hellmich M, Neise M, et al. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist 2007;12:748-55
18. Steinmetz HT, Tsamaloukas A, Schmitz S, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010;19:261-9
19. Mortensen FV, Jensen LS, Sorensen HT, et al. Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study. Transfusion 2011;51:259-63
20. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113:3406-17
21. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124
22. Agarwal AK. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease. Expert Opin Drug Saf 2009;8:145-53
23. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Canc Res 2011;17:6373-80
24. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
25. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49
26. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41
27. Marchal C, Misset JL, Casadevall N, et al. [Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)]. Cancer Radiother 2008;12:126-33
28. Ray-Coquard I, Kassab-Chahmi D, Casadevall N, et al. [Clinical practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]. Bulletin du cancer 2008;95:433-41
29. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
30. Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebocontrolled GHSG HD15EPO trial. J Clin Oncol 2010;28:2239-45
31. Delarue R, Haioun C, Fornecker L, et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study. J Clin Oncol 2011;29:abstr 9048
32. Blohmer JU, Paepke S, Sehouli J, et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol 2011;29:3791-7
33. Nitz U, Gluz O, Oberhoff C, et al. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA trial 34th Annual San Antonio Breast Cancer Symposium 2011, 6-10 December 2011, San Antonio, TX, USA, Abstract PD07-06
34. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, doubleblind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17
35. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25
36. Steinmetz T, Totzke U, Soling U, et al. Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia-examination of practice in Germany. Curr Med Res Opin 2008;24:2751-6
37. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010
38. Bohlius J, Langensiepen S, Schwarzer G, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004(3):CD003407
39. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006(3):CD003407
40. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407
41. Christodoulou C, Dafni U, Aravantinos G, et al. Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy. Anticancer Res 2009;29:693-702
42. Nagel S, Kellner O, Engel-Riedel W, et al. Addition of darbepoetin alfa to dosedense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Clin Lung Canc 2011;12:62-9
43. Carteni G, Giannetta L, Ucci G, et al. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Support Care Cancer 2007;15:1057-66
44. Bell D, Grimes D, Gurney H, et al. Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. Intern Med J 2008;38:751-7
45. Glaspy JA, Charu V, Luo D, et al. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer 2009;115:1121-31
46. Rorth M, Madsen KR, Burmolle SH, et al. Effects of darbepoetin alfa with exercise in cancer patients undergoing chemotherapy: an explorative study. Scand J Med Sci Sports 2011;21:369-77
47. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
48. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009(3):CD007303